Price movement over the last 24 hours
Abbott Laboratories vs ARK Fintech Innovation ETF — how do they compare? Abbott Laboratories trades at $95.53 (market cap $166.94B), while ARK Fintech Innovation ETF trades at $40.55. The key difference: Abbott Laboratories pays a 2.63% dividend while ARK Fintech Innovation ETF pays none. Which is the better fit depends on your goals.
| ABT | ARKF | |
|---|---|---|
Market Cap | $166.94B | — |
Sector | Health | Sector/Thematic |
52-Week High | $136.62 | $58.82 |
52-Week Low | $82.57 | $36.14 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | — |
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
ARKF trades at $42.04, up 2.61% with strong technical momentum showing bullish signals across moving averages and oscillators. The stock faces resistance at $43-44 while finding support at $41-42 levels. Recent coverage highlights institutional interest in the fund's holdings, particularly in technology stocks favored by prominent investors.
The ETF's exposure to high-growth technology stocks positions it for potential upside, though elevated RSI levels suggest near-term consolidation risk. Investors face concentration risk in the fund's top holdings and market volatility sensitivity, requiring careful position sizing given the aggressive growth focus.
Trailing returns across standard periods
Latest headlines on both assets
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →ARKF is an actively managed ETF that invests in companies leading the way in fintech innovation. Key themes include mobile payments, digital wallets, blockchain technology, and frictionless funding platforms.
Read more on ARKF →